- Home
- IBIO vs GANX Comparison
IBIO vs GANX Comparison
Compare IBIO & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBIO | GANX |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.2M | 78.2M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IBIO | GANX |
|---|---|---|
| Price | $1.43 | $1.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.75 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 897.8K | 461.4K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.08 | 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $1.41 |
| 52 Week High | $3.82 | $4.34 |
Technical Indicators
Market Signals| Indicator | IBIO | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 32.25 | 33.99 |
| Support Level | $0.97 | $1.60 |
| Resistance Level | $1.80 | $2.09 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 5.06 | 12.30 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.